KP-1019

Investigational

Stereochemistry	ACHIRAL
Molecular Formula	C7H7N2.2C7H6N2.4Cl.Ru
Molecular Weight	598.3
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0
Stereo Comments	octahedral structure with two trans N-donor indazole and four chloride ligands in the equatorial plane.

[Cl-].[Cl-].[Cl-].[Cl-].[Ru+3].N1N=CC2=C1C=CC=C2.N3N=CC4=C3C=CC=C4.N5[NH+]=CC6=C5C=CC=C6

InChIKey=PJXASRBEMZORRI-UHFFFAOYSA-K

InChI=1S/3C7H6N2.4ClH.Ru/c3*1-2-4-7-6(3-1)5-8-9-7;;;;;/h3*1-5H,(H,8,9);4*1H;/q;;;;;;;+3/p-3

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Targets

Primary Target	Pharmacology	Condition	Potency
GRP78 pathway 3 Target ID: GRP78 pathway Sources: http://intezyne.com/assets/patents-and-publications/posters/IT-139/4-IT-139-Thompson-et-al-NKP1339-MTD-ASCO-2012.pdf \| https://adisinsight.springer.com/drugs/800034247	Inhibitor 8504
G2/M cell cycle arrest 3 Target ID: G2/M cell cycle arrest Sources: https://www.medchemexpress.com/nkp-1339.html	Activator 1447
DNA synthesis involved in DNA replication 11 Target ID: GO:0090592 Sources: https://www.medchemexpress.com/nkp-1339.html \| https://adisinsight.springer.com/drugs/800034247	Blocker 555

PubMed

Title	Date	PubMed
Characterizing activation mechanisms and binding preferences of ruthenium metallo-prodrugs by a competitive binding assay.	2017-12	28739166
Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing Mouse.	2017-01-23	28112202
Water-soluble Ru(II)- and Ru(III)-halide-PTA complexes (PTA=1,3,5-triaza-7-phosphaadamantane): Chemical and biological properties.	2016-07	26920229
X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism.	2016-06-23	27196130
Molecular mode of action of NKP-1339 - a clinically investigated ruthenium-based drug - involves ER- and ROS-related effects in colon carcinoma cell lines.	2016-06	26988975
CF3 Derivatives of the Anticancer Ru(III) Complexes KP1019, NKP-1339, and Their Imidazole and Pyridine Analogues Show Enhanced Lipophilicity, Albumin Interactions, and Cytotoxicity.	2016-05-16	27143338
Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort.	2016	28848672
Improved reaction conditions for the synthesis of new NKP-1339 derivatives and preliminary investigations on their anticancer potential.	2015-01-14	25385191

Substance Class	Chemical Created by `admin` on `Tue Apr 01 21:11:09 GMT 2025` Edited by `admin` on `Tue Apr 01 21:11:09 GMT 2025`
Record UNII	DIO8FKP4J2
Record Status	`Validated (UNII)`
Record Version

Name

Type

Language

FFC-14A

Preferred Name

English

KP-1019

Code

English

RUTHENATE(1-), TETRACHLOROBIS(1H-INDAZOLE-.KAPPA.N2)-, (OC-6-11)-, HYDROGEN, COMPD. WITH 1H-INDAZOLE (1:1:1)

Systematic Name

English

Code System Code Type Description

CAS

124875-20-3